Why India-UK FTA may push medicines out of ordinary Indians’ reach https://thefederal.com/category/business/why-india-uk-fta-may-push-medicines-out-of-ordinary-indians-reach-198364
India is set to sign an FTA with the UK on July 24; most details are public except the IPR chapter, The IPR chapter may include provisions like evergreening of patents, extended patent terms, and data exclusivity, potentially raising medicine costs and limiting access for ordinary Indians.
Big Pharma advantage: Leaked drafts suggest the deal could weaken safeguards, block public objections to patents, and protect pharmaceutical monopolies far beyond global norms (TRIPS), benefitting multinational drug companies.